Rationale, development, and clinical outcomes of a multidisciplinary amiodarone clinic

Pharmacotherapy

Volumn 18, Issue 6 II, 1998, Pages

  Sanoski, Cynthia A ^b   Schoen, Marieke D ^a   Gonzalez, Rose C ^a   Avitall, Boaz ^a   Bauman, Jerry L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

ADULT; AGED; ASTHMA; CONFERENCE PAPER; DATA BASE; DOSE CALCULATION; DRUG MECHANISM; DRUG MONITORING; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LIVER FUNCTION TEST; LUNG FIBROSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; OUTPATIENT DEPARTMENT; PRACTICE GUIDELINE; QT INTERVAL; THORAX RADIOGRAPHY; THYROID FUNCTION TEST; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0031726211     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Phillips BG, Bauman JL. Prescribing trends and pharmacoeconomic considerations in the treatment of arrhythmias. Focus on atrial fibrillation and flutter. Pharmacoeconomics 1995;7:521-33.
2. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
3. Gosselink AT, Crijins HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992;267;3289-93.
4. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter Am J Cardiol 1995;76:47-50.
5. Herre JM, Sauve MJP, Malone P, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989;13:442-9.
6. Weinberg BA, Miles WM, Klein LS, et al. Five year follow-up of 589 patients treated with amiodarone. Am Heart J 1993;125:109-20.
7. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993;72:280-7.
8. Doval HC, Nul DR, Grancelli HO, et al, for Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-8.
9. Singh SN, Fletcher RD, Fisher SG, et al, for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. Amiodarone in patients with congestive heart failure with asymptomatic ventricular arrhythmias. N Engl J Med 1995;333:77-82.
10. Julian DG, Camm AJ, Frangin G, et al, for the European Myocardial Infarct Amiodarone Trial (EMIAT) Investigators. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-74.
11. Cairns JA, Connolly SJ, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT) Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997;349:675-82.
12. Kenn NZ, Aragon E, Faitel K, Frumin H, Rubenfire M. Long-term efficacy and toxicity of high- and low-dose amiodarone regimens. J Clin Pharmacol 1989;29:418-23.
13. Bauman JL, Berk SI, Hariman RJ, et al. Amiodarone for sustained ventricular tachycardia: efficacy, safely, and factors influencing long-term outcome. Am Heart J 1987;114: 1436-44.
14. Wilson JS, Podrid PJ. Side effects from amiodarone. Am Heart J 1991;121:158-71.
15. Murphy JA, Fitzsimons BM, Meute MA, Wilkinson WC, Luck JC, Wiley SW. Amiodarone: a postmarketing evaluation of monitoring for drug-induced toxicity. Drug Intell Clin Pharm 1990;24:1001-6.
16. Singh BN. How to follow a patient on chronic amiodarone therapy. Choices in Cardiology 1989;3(suppl 3):16-20.
17. Singh BN. Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. Clin Cardiol 1997;20:608-18.
18. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects. A review with special reference to torsades de pointes tachycardia. Ann Intern Med 1994;121:529-35.
19. Sanoski CA, Bauman JL. Long-term characterization of the amiodarone-warfarin drug interaction [abstr]. J Am Coll Cardiol 1998;31:507-8A.
20. Hunt D, Kertes P, Venables S, Callaghan J, Harrison LC. Exacerbation of bronchial asthma following treatment with amiodarone. Demonstration of an antiadrenergic effect in vitro. Chest 1984;86:492-4.